NGD 971

Drug Profile

NGD 971

Alternative Names: CP457920; NGD 97-1

Latest Information Update: 27 Jan 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neurogen Corporation
  • Developer Neurogen Corporation; Pfizer
  • Class Antidementias; Neuroprotectants; Small molecules
  • Mechanism of Action GABA A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 24 Jan 2011 Discontinued - Phase-II for Vascular dementia in USA (unspecified route)
  • 10 May 2004 Discontinued - Phase-II for Alzheimer's disease in USA (unspecified route)
  • 05 May 2004 Data presented at the 56th Annual Meeting of the American Academy of Neurology (AAN-2004) have been added to the Alzheimer's disease therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top